Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai To Further Strengthen Strategic Investment In Japan And The U.S.

This article was originally published in PharmAsia News

Executive Summary

At Eisai's third quarter earnings announcement meeting, President Haruo Naito stated that Eisai would further strength strategic investment in the U.S and Japan. Naito does not think that in the following 10 years, BRIC (Brazil, Russia, India and China) countries would have a drug market equal in size to the American market. He also does not believe the four countries would form a drug market cluster similar to the American one. Based on the predication, Eisai is going to set Japanese and American markets as its priorities, and will further invest in these markets to strength their foothold. Last December, Eisai announced its acquisition of U.S. biopharmaceutical company MGI Pharma for $3.9 billion dollars in cash. (Click here for more-Japanese language

You may also be interested in...

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts